» Articles » PMID: 4007029

The Acute Changes in Serum Binding of Disopyramide and Flecainide After Myocardial Infarction

Overview
Specialty Pharmacology
Date 1985 Jan 1
PMID 4007029
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

In the serum basic drugs are principally bound to alpha1-acid glycoprotein (AAG). Following acute myocardial infarction it has been shown that the levels of AAG rise. The serum levels of total protein, albumin, AAG and the protein binding of 2 antiarrhythmic drugs which are bases, disopyramide and flecainide, was measured in vitro with blood samples from eleven patients taken over the first 5 days following myocardial infarction. Mean AAG levels significantly increased from 1.04 g/l on Day 1 to 1.80 g/l on Day 5. The binding of disopyramide, which is highly bound, rose from 80% to 87%, representing a 35% decrease in free drug concentration. In contrast the binding of flecainide fell from 61% to 53%, a 20% increase in free drug concentration. These data suggest that although the binding of strongly bound drugs responds appropriately to increases in binding protein after acute myocardial infarction, poorly bound drugs are displaced from binding sites possibly by endogenous substances. Since the pharmacological effects of a drug are related to its free (unbound) concentration, the changes in the proportions of free to bound drug after myocardial infarction may have important clinical implications.

Citing Articles

Pediatric flecainide pharmacogenomics: a roadmap to delivering precision-based care to pediatrics arrhythmias.

Palmen R, Walton M, Wagner J Front Pharmacol. 2025; 15:1477485.

PMID: 39741635 PMC: 11686437. DOI: 10.3389/fphar.2024.1477485.


Therapeutic drug monitoring of antiarrhythmic drugs.

Jurgens G, Graudal N, Kampmann J Clin Pharmacokinet. 2003; 42(7):647-63.

PMID: 12844326 DOI: 10.2165/00003088-200342070-00004.


Disopyramide in acute myocardial infarction: problems with changing pharmacokinetics.

Elliott H, Thomson A, Bryson S Eur J Clin Pharmacol. 1986; 30(3):345-7.

PMID: 3732373 DOI: 10.1007/BF00541541.


Gallopamil binding to human serum proteins.

Rutledge D, Pieper J Eur J Clin Pharmacol. 1987; 33(4):375-80.

PMID: 3443143 DOI: 10.1007/BF00637633.


Disopyramide. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias.

Brogden R, Todd P Drugs. 1987; 34(2):151-87.

PMID: 3304965 DOI: 10.2165/00003495-198734020-00001.

References
1.
Pike E, Kierulf P, Skuterud B, Bredesen J, Lunde P . Drug binding in sera deficient in lipoproteins, albumin or orosomucoid. Br J Clin Pharmacol. 1983; 16(3):233-9. PMC: 1427992. DOI: 10.1111/j.1365-2125.1983.tb02155.x. View

2.
Barchowsky A, SHAND D, Stargel W, Wagner G, Routledge P . On the role of alpha 1-acid glycoprotein in lignocaine accumulation following myocardial infarction. Br J Clin Pharmacol. 1982; 13(3):411-5. PMC: 1402123. DOI: 10.1111/j.1365-2125.1982.tb01394.x. View